Loading…
Janux Therapeutics, Inc. is projected to rise to $17.13 by 2027, a +19% move from its current price of $14.44. JANX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean neutral.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $14.20 | $14.44 | $14.68 | 0.00% |
| May 30 | $14.10 | $14.44 | $14.79 | 0.00% |
| May 31 | $14.03 | $14.44 | $14.87 | 0.00% |
| Jun 1 | $13.96 | $14.44 | $14.93 | 0.00% |
| Jun 2 | $13.91 | $14.44 | $14.99 | 0.00% |
| Jun 3 | $13.86 | $14.44 | $15.05 | 0.00% |
| Jun 4 | $13.81 | $14.44 | $15.10 | 0.00% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $13.81 | $14.44 | $15.10 | 0.00% |
| Week 2 | $13.56 | $14.44 | $15.38 | +0.01% |
| Week 3 | $13.37 | $14.44 | $15.60 | +0.01% |
| Week 4 | $13.21 | $14.44 | $15.78 | +0.02% |
| Week 5 | $13.08 | $14.44 | $15.95 | +0.02% |
| Week 6 | $12.95 | $14.44 | $16.10 | +0.02% |
| Week 7 | $12.84 | $14.44 | $16.25 | +0.03% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Janux Therapeutics, Inc. is a clinical stage biopharmaceutical company that develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer.
The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases.
The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc.
was incorporated in 2017 and is headquartered in San Diego, California.
Janux Therapeutics, Inc. (JANX) is a healthcare stock currently priced at $14.52 with a market cap of $885.49M, and it is ranked 2624.
The 30-day technical picture shows NEUTRAL sentiment, RSI14 at 50, SMA50 at $14.44, SMA200 at $18.94, with a support at $13.81 and a resistance at $15.87. The 30-day price range spans from $12.91 to $16.33, and the stock carries an annualized volatility of 30%.
Looking ahead, the multi-year forecast shows a rising path in average price and ROI from 2026 through 2050, with 2026 avg $14.52 and 2050 avg $90.94, while max values rise to as high as $148.81 in 2050.
A major floor 15.7% below — a decisive break under it would weaken the trend.
The nearest floor, 4.4% below — buyers have tended to step in here.
The nearest ceiling, 9.9% above — a clean break opens room to run.
A major ceiling 16.1% above — clearing it would confirm fresh momentum.
Key JANX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of JANX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $14.43 | Buy | $14.39 | Buy |
| MA 10 | $14.29 | Buy | $14.35 | Buy |
| MA 20 | $14.32 | Buy | $14.40 | Buy |
| MA 50 | $14.47 | Sell | $14.50 | Sell |
| MA 100 | $14.09 | Buy | $15.45 | Sell |
| MA 200 | $18.86 | Sell | $18.64 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.27 | Neutral |
| Stoch RSI (14) | 88.88 | Sell |
| CCI (20) | 46.49 | Neutral |
| Williams %R (14) | -21.25 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 1.87 | Buy |
| Bollinger %B (20,2) | 0.64 | Neutral |
| Stochastic %K (14) | 78.75 | Neutral |
| TRIX (15) | -0.09 | Sell |
| Awesome (5,34) | -0.23 | Sell |
| Ultimate (7,14,28) | 61.04 | Neutral |
| Momentum (10) | 0.03 | Buy |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 14.56 | Sell |
| ADX (14) | 8.99 | Neutral |
| ATR (14) | 0.21 | Info |
The near-term technical picture is NEUTRAL. The RSI 14 is 50, indicating a balanced momentum stance near the midpoint.
The stock trades relative to its moving averages, with SMA50 at $14.44 and SMA200 at $18.94. A support level is identified at $13.81 and a resistance at $15.87. The 30-day price range runs from a low of $12.91 to a high of $16.33.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.18 | $14.44 | $20.46 | 0% | Neutral | |
| $13.99 | $17.13 | $21.95 | +19% | Neutral | |
| $14.83 | $18.48 | $24.30 | +28% | Bullish | |
| $15.91 | $20.13 | $27.02 | +39% | Bullish | |
| $16.10 | $20.64 | $28.20 | +43% | Bullish | |
| $17.49 | $22.69 | $31.48 | +57% | Bullish | |
| $19.77 | $25.95 | $36.50 | +80% | Bullish | |
| $22.61 | $29.98 | $42.71 | +108% | Bullish | |
| $24.56 | $32.88 | $47.40 | +128% | Bullish | |
| $24.71 | $33.39 | $48.67 | +131% | Bullish | |
| $34.63 | $48.82 | $74.54 | +238% | Bullish | |
| $60.79 | $91.87 | $150.33 | +536% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $12.18 | $14.44 | $16.92 | +0.00% |
| June 2026 | $12.33 | $14.39 | $17.11 | -0.37% |
| July 2026 | $12.31 | $14.45 | $17.34 | +0.42% |
| August 2026 | $12.80 | $15.08 | $18.24 | +4.38% |
| September 2026 | $13.13 | $15.53 | $18.89 | +2.99% |
| October 2026 | $13.15 | $15.61 | $19.09 | +0.52% |
| November 2026 | $13.44 | $16.01 | $19.67 | +2.52% |
| December 2026 | $13.89 | $16.58 | $20.46 | +3.57% |
Click any year to see its month-by-month JANX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, JANX could reach as high as $20.46, with a base case around $14.44 and support toward $12.18 — roughly 0% from $14.44. Price action looks broadly range-bound.
Expect JANX to range from $13.99 to $21.95 through 2027. The $17.13 average target implies a +19% move from current prices. That is up +19% on the projected 2026 average. A consolidation phase looks the most probable path here.
The JANX price prediction for 2028 points to an average of $18.48 (low $14.83, high $24.30) — a potential gain of +28% on today's $14.44. Momentum favours further upside here.
In 2029, JANX is projected to trade between $15.91 and $27.02, averaging $20.13 — a potential gain of +39% from today's $14.44. That is up +9% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Janux Therapeutics, Inc.'s 2030 outlook centres on $20.64, within a $16.10 to $28.20 range. That is up +3% on the projected 2029 average. That marks a +43% change versus current levels. Momentum favours further upside here.
By 2031, JANX could reach as high as $31.48, with a base case around $22.69 and support toward $17.49 — roughly +57% from $14.44. Buyers look set to stay in control over this stretch.
Expect JANX to range from $19.77 to $36.50 through 2032. The $25.95 average target implies a +80% move from current prices. That is up +14% on the projected 2031 average. Momentum favours further upside here.
The JANX price prediction for 2033 points to an average of $29.98 (low $22.61, high $42.71) — a potential gain of +108% on today's $14.44. Buyers look set to stay in control over this stretch.
In 2034, JANX is projected to trade between $24.56 and $47.40, averaging $32.88 — a potential gain of +128% from today's $14.44. That is up +10% on the projected 2033 average. Momentum favours further upside here.
Janux Therapeutics, Inc.'s 2035 outlook centres on $33.39, within a $24.71 to $48.67 range. That is up +2% on the projected 2034 average. That marks a +131% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, JANX could reach as high as $74.54, with a base case around $48.82 and support toward $34.63 — roughly +238% from $14.44. Momentum favours further upside here.
Expect JANX to range from $60.79 to $150.33 through 2050. The $91.87 average target implies a +536% move from current prices. That is up +88% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in JANX today (≈ 69.252078 JANX) could be worth
$6,362.49
+$5,362.49 (+536%) by 2050 · US Dollar
Based on the average projected JANX price of $91.87 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in JANXwould be worth at today's price.
$1,000 invested in JANX on May 27, 2025 (≈ 41.254126 JANX) would be worth
$595.71
-$404.29 (-40.4%) today · 0.60× · US Dollar
Based on a JANX entry price of $24.24 vs. today's $14.44.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $14.4 | $1,002.78 | +0.3% |
| 1 month ago | $15.23 | $948.13 | -5.2% |
| 3 months ago | $13.8 | $1,046.38 | +4.6% |
| 6 months ago | $34.09 | $423.58 | -57.6% |
| 1 year ago | $24.24 | $595.71 | -40.4% |
| All time (5.0y) ago | $25.15 | $574.16 | -42.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our JANX forecast.
Our base-case forecast reaches $29.00 around 2033.
Implied market cap at $29.00: $1.77B
The multi-year forecast shows a bullish trajectory from 2028 onward, with the average price rising across the years and increasingly substantial ROIs. In 2026 the avg is $14.52 with a 0% ROI and neutral sentiment; by 2027 the avg is $17.12 (ROI 17.9%), and 2028 shows $18.59 (ROI 28%). The 2029 forecast sits at $20.22 (ROI 39.3%), and 2030 at $20.55 (ROI 41.5%), all with bullish sentiment.
From 2031 through 2035, the averages continue to rise to $22.72, $25.96, $29.80, $32.87, and $33.22 respectively, with ROIs of 56.5%, 78.8%, 105.3%, 126.4%, and 128.8%. The forecast then accelerates toward 2040, with avg $48.72 (ROI 235.5%) and a max of $74.40; and by 2050, the avg is $90.94 (ROI 526.3%) with a max of $148.81. Sentiment is listed as BULLISH from 2028 onward.
These figures are estimates and not guarantees; actual results will vary based on a range of factors. Investors should consider the long horizon and inherent uncertainty when evaluating these forecasts.
Tap a question to reveal the answer.
The forecast for 2030 shows an average price of $20.55 with a min of $16.02, a max of $28.07, and an ROI of 41.5%; sentiment is BULLISH.
Forecasts show rising averages over time, with 2027 avg $17.12 (ROI 17.9%), 2030 avg $20.55 (ROI 41.5%), and 2050 avg $90.94 (ROI 526.3%), along with bullish sentiment from 2028 onward. These are estimates not guarantees.
The max forecast by 2050 is $148.81, indicating a potential to exceed $100 according to the modeled path; however, these are not guarantees.
Current price is $14.52 and market cap is $885.49M.
The 2040 forecast shows an average price of $48.72 with a min of $34.56, a max of $74.40, and an ROI of 235.5%; sentiment is BULLISH.
Janux Therapeutics, Inc. Community Discussion
0Share your Janux Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.